Boston-based Alexion Pharmaceuticals develops medicine for rare diseases. Among its products are a treatment for a rare blood disease as well as the only approved complement inhibitor to treat a rare central nervous system disorder. In April, the company reported first quarter total revenue of $1.6 billion, a 13% increase from the same quarter last year. After almost 30 years as an independent company, Alexion was acquired by AstraZeneca in June, 2021. Nearly 90% of Alexion’s shares are held by institutions, including its two biggest shareholders, Vanguard Group and BlackRock.
Lists ranking Alexion Pharmaceuticals
Latest news for Alexion Pharmaceuticals